Senin, 08 Juni 2026 - 15:04 WIB

Find and Follow Us

Global Markets

IHSG 5,351.12 -4.35%

S&P 500 7,383.74 -2.64%

NASDAQ 25,709.43 -4.18%

Dow Jones 50,866.78 -1.35%

FTSE 100 10,333.91 -0.33%

CAC 40 8,158.63 -0.73%

Nikkei 225 64,024.60 -3.85%

Hang Seng 24,632.11 -1.32%

Shanghai 3,959.34 -1.70%

KOSPI 7,484.41 -8.29%

STI 4,966.44 -1.65%

ASX 200 8,625.10 -0.70%

Sensex 73,770.71 -0.64%

Gold 4,323.20 -0.32%

Silver 67.20 -2.54%

Oil (WTI) 94.31 +4.16%

Brent 97.28 +4.50%

Copper 6.30 +0.55%

Gas Alam 3.14 -2.91%

Bitcoin 63,229.52 -0.02%

Ethereum 1,671.60 -0.88%

USD/IDR 18,170.00 +1.19%

EUR/USD 1.15 -0.79%

Advertisement

Ilustrasi Kalbe Farma Obat (Photo by Sriwijaya Post-Tribunnews.com)

Kalbe Farma Lakukan Uji Klinik Fase-3 Obat Anemia Efepoetin Alfa, Pasien Pertama Asal Malaysia

Redaksi • 25 Agustus 2020

Latest Updates

- Advertisement -

Ilustrasi Kalbe Farma Obat (Photo by Sriwijaya Post-Tribunnews.com)

12:15 WIB • 25 Agustus 2020

Kalbe Farma Lakukan Uji Klinik Fase-3 Obat Anemia Efepoetin Alfa, Pasien Pertama Asal Malaysia

PT Kalbe Farma Tbk (Kalbe) melalui anak usaha Kalbe-Genexine Biologics (KGBio) saat ini telah “meng-enroll” pasien pertama…